Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Businessweek Archives

A Biotech With Testosterone

Inside Wall Street


If you don't believe biotechs are back, take a gander at the sizzle of Bio-Technology General (BTGC): Its stock shot from 5 a share on Apr. 10, 1996, to 17 3/4 on Feb. 20, 1997. Profit-taking nudged it down to 14 1/8 by Mar. 18.

Time to bail out or avoid the stock? Not by a long shot, says one money manager who has been buying each time the stock turns down. And some analysts, whose price targets for Bio-Technology have been pierced, continue to be bullish on the company.

"We are raising our 12-month price objective from 16 to 20," says analyst Paul Woodhouse of Merrill Lynch, in part to accommodate an improvement in earnings. He had a price objective of 12 when the stock was at 7 in November and then raised it to 16 in January when it hit 12.

Bio-Technology is "one of the most exciting earnings and investment stories in the Merrill Lynch drug stock universe," says Woodhouse. The company moved into the black in 1995 when it introduced its first major product, Oxandrin, used for the treatment of involuntary weight loss brought on by cancer, AIDS, or severe trauma. He projects sales of Oxandrin of $39 million in 1997 and $60 million next year. The product, he says, will be the company's main growth engine for the next two years. Another product selling well, says Woodhouse, is Bio-Tropin, a hormone for treating growth disorders.

New products include: Androtest-SL, testosterone that is taken orally for treatment of impotence, poor muscle development, and bone loss, already submitted to the Food & Drug Administration for approval; and OxSODrol, in its third clinical trials, for the prevention of the severe lung ailments that affect 30% of premature babies.

Woodhouse expects Bio-Technology to make 44 cents a share in 1997 and 76 cents in 1998, up from last year's 26 cents.By GENE G. MARCIALReturn to top

Return to top

blog comments powered by Disqus